Announcements
- Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
- Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH
- Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traité
- Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
- Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
- Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)
- Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur
- Inventiva announces the nomination of Andre Turenne as Director
- Inventiva reports its 2023 full-year results
- Inventiva publie ses résultats annuels 2023
More ▼
Key statistics
On Friday, Inventiva SA (6IV:MUN) closed at 3.42, -19.43% below its 52-week high of 4.25, set on Jun 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.42 |
---|---|
High | 3.42 |
Low | 3.42 |
Bid | 3.49 |
Offer | 3.61 |
Previous close | 3.42 |
Average volume | 302.44 |
---|---|
Shares outstanding | 52.48m |
Free float | 42.01m |
P/E (TTM) | -- |
Market cap | 178.95m EUR |
EPS (TTM) | -2.45 EUR |
Data delayed at least 15 minutes, as of May 17 2024 07:06 BST.
More ▼